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There is renewed interest in identifying organic waste solutes
that are normally excreted by the kidneys and must be
removed by renal replacement therapy when the kidneys fail.
A large number of these waste solutes are produced by colon
microbes. Mass spectrometry is expanding our knowledge of
their chemical identity, and DNA sequencing technologies
are providing new knowledge of the microbes and metabolic
pathways by which they are made. There is evidence that the
most extensively studied of the colon-derived solutes,
indoxyl sulfate and p-cresol sulfate, are toxic. Much more
study is required to establish the toxicity of other solutes in
this class. Because they are made in an isolated compartment
by microbes, their production may prove simpler to suppress
than the production of other waste solutes. To the extent
that they are toxic, suppressing their production could
improve the health of renal failure patients without the need
for more intensive or prolonged dialysis.
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The kidney excretes a large number of organic waste solutes
whose origins are diverse. Better knowledge of these
solutes could lead to improved treatment for patients with
kidney failure. Many waste solutes are produced by colon
microbes. There is reason to suppose that some of these
compounds, which are foreign to mammalian metabolism,
have toxic effects. Because they are made in an isolated body
compartment by microbes, their production may prove
simpler to suppress than the production of other uremic
waste solutes.
THE COLON MICROBIOME
Our human bodies are heavily colonized by microbes.1 The
largest collection of these microbes, with a density of 1010 to
1012 cell/ml, inhabits the colon.1–3 In cell number and even
more in gene number, the colon microbial population or
colon ‘microbiome’ dwarfs its human host. DNA sequencing
technology has greatly increased our knowledge of the
diversity and function of the colon microbes. In mammalian
evolution, their chief value has been to extract energy from
plant polysaccharides that cannot be digested by host
enzymes. Microbial fermentation of these polysaccharides
yields short chain fatty acids. While this process provides
only a small portion of the energy used daily in humans
consuming an ‘industrialized’ diet, it can be a crucial source
of energy when the diet contains more unprocessed plant
food.4 Colon microbes also provide micronutrients including
vitamins and produce hormones that promote fat storage.
Through co-evolution with their mammalian hosts, they have
developed the capacity to limit colonization of the gut by
pathogens and to stimulate the host immune system in useful
ways. The action of colon microbes on foodstuffs and
intestinal secretions, however, generates numerous organic
compounds in addition to those that are useful to their
host.5 The burden of excreting some of these compounds in
the urine represents a biological price paid by the host
for harboring the microbes. Colon-derived solutes that are
normally excreted in the urine accumulate in the plasma
when the kidneys fail and may contribute to uremic
toxicity.6,7
UREMIC SOLUTES PRODUCED BY COLON MICROBES
While knowledge of the colon’s microbial diversity is new, the
hypothesis that colon microbes produce toxic solutes is old.
In his original description of hemodialysis, Kolff8 noted that
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‘‘Besides indoxyl still other various putrefaction products
of the intestine may be increased in the blood in renal
insufficienty [sic]. They are phenoles, cresoles, aromatic
oxyacids, and other aromatic substances.’’
Putrefaction—the breakdown of proteins by bacteria—
excited both scientific and popular interest in the late
nineteenth and early twentieth centuries.9 The Russian Nobel
Laureate Metchnikoff believed that in modern humans the
colon was not only useless but harmful, and that ‘autointox-
ication’ caused by colonic putrefaction accelerated aging and
caused disease. He advocated the consumption of milk
soured by lactic acid–producing bacteria to inhibit proteolysis
in the colon. The British surgeon W. Arbuthnot Lane went
further and bypassed the colon to treat diseases ranging from
tuberculosis to rheumatoid arthritis.9 The autointoxication
theory had been largely discredited by Kolff ’s time, but it had
left behind a legacy of solid biochemical research. Gut
bacteria had been shown to degrade tryptophan into a variety
of indoles and phenylalanine and tyrosine into a variety of
phenyl compounds. Some of these compounds were found
first in the urine of normal humans and then in the plasma of
patients with kidney failure.10
The colon-derived uremic solutes that have been most
extensively investigated are indoxyl sulfate and p-cresol
sulfate, which are formed as depicted in Figure 1.11,12 These
compounds have received the most attention because they are
formed in relatively large quantities and therefore proved
easiest to measure. As reviewed below, there is considerable,
though not conclusive, evidence that they are toxic. Indoxyl
sulfate and p-cresol sulfate are only two, however, of a very
large number of colon-derived uremic solutes. Other
compounds in this class may be more toxic, although they
are present in lower concentration. Between 1940 and 1990,
numerous indoles and phenols were identified in uremic
plasma first by paper and then gas chromatography.10,13,14
Researchers hypothesized that many of them were made by
colon microbes. In most cases, however, their origin was not
confirmed and there has been very little evaluation of their
toxicity.
The application of mass spectrometry has the power to
greatly enlarge our knowledge of uremic solutes in general
and of colon-derived uremic solutes in particular.5,15,16 High-
resolution detectors that resolve the mass to charge (m/z)
ratios of ions to within a few parts per million may prove
particularly valuable in uremia research. These instruments
make it possible to perform ‘nontargeted’ metabolomic
studies in which numerous unnamed chemical features
characterized only by their m/z ratios are detected along
with known compounds. Kikuchi et al.17 first used non-
targeted mass spectrometry to detect solutes that accumulate
in the plasma of rats with renal insufficiency, and Sato et al.18
have recently demonstrated the capacity of nontargeted mass
spectrometry to detect both known and unknown com-
pounds in a study evaluating the effect of hemodialysis on
plasma solute concentrations.
Solutes produced by colon microbes can be identified by
combining mass spectrometry with maneuvers that suppress
microbial solute production. A pioneering study by Wikoff
et al.5 used high-resolution mass spectrometry to identify
plasma solutes produced by gut microbes in rats. Of several
thousand features detected in plasma, B10 percent was
considered to vary in concentration between conventional
and germ-free rats. The majority of these features was less
prevalent in the germ-free animals, and thus considered to be
of microbial origin. Of note, some features considered to be
of microbial origin were later found to accumulate in the
plasma of mice lacking the renal anion transporter OAT1,
suggesting that they are largely removed from the body by
renal tubular secretion.19 Kikuchi et al.20 subsequently used
mass spectrometry to identify solutes in whose plasma levels
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Figure 1 |Microbial generation of indoxyl sulfate from tryptophan and of p-cresol sulfate from tyrosine. Tryptophan is converted to
indole by tryptophanase, which is found only in microbes. Absorption of indole in the colon is then followed by oxidation and sulfation in
the liver. Tyrosine is converted by microbes in two steps to 4-hydroxy phenylacetic acid, which is then decarboxylated to p-cresol by an
enzyme that has been shown to be present most notably in Clostridium difficile.47 Sulfation of p-cresol is then accomplished in the colonic
epithelium and possibly also in the liver. Older reports measured p-cresol rather than p-cresol sulfate in the plasma of dialysis patients
because assay techniques used acidification that hydrolyzed the conjugate.12 Lesser portions of both indoxyl and p-cresol are conjugated
with glucuronic acid rather than sulfuric acid.
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were reduced by the administration of the oral sorbent AST-
120 in rats with renal insufficiency. We recently used an
approach similar to that used by Wikoff et al.5 to compare
plasma solute profiles in dialysis patients with and without
colons.21 The difference between patients with and without
colons was readily apparent on superficial examination of
mass spectra, as illustrated in Figure 2. Statistical analysis
identified more than 20 mass spectrometric features that were
colon-derived. Of note, the great majority of these was more
prominent in dialysis patients than normal subjects and so
could be considered to represent uremic solutes.
A weakness of nontargeted mass spectrometry is that it
provides mass values but not chemical identities for the
numerous features detected. Chemical identification requires
further analysis of samples containing reagent standards and/
or ‘MS/MS’ measurements of the ion masses produced by
fragmentation of the original ions.22 Only a small number of
the colon-derived solutes recently detected by mass spectro-
metry have been chemically identified. Wikoff et al.5
identified only 16 of several hundred features that were more
prominent in the plasma of conventional than germ-free rats.
These included three indole and six phenyl compounds. We
identified three indole and two phenyl compounds that were
present at higher concentration in dialysis patients with
colons than in dialysis patients without colons and normal
subjects.21 Part of the problem is that organic waste
compounds are often conjugated to form sulfates, glucuro-
nides, or other complex ions. Conjugation, as illustrated for
p-cresol and indoxyl in Figure 1, can at once reduce the
toxicity of waste compounds and facilitate their excretion by
tubular secretion. But conjugation makes it harder to
determine the chemical identity of features for which mass
spectrometry provides only the m/z ratio. Standard databases
usually do not contain mass values for conjugates of
Indoxyl
sulfate
Hippurate
α-N-phenylacetyl-
glutamine
p-Cresol
sulfate
Time (min)
Time (min)
α-N-phenylacetyl-
glutamine
8 8.17Time (min) 12.5 12.70
m /z = 263.1037 m /z = 264.0876
Amplitude
2×107
Amplitude
3×105
15141312111098765432
Figure 2 | The identification of colon-derived solutes by mass spectrometry. The upper part of the figure shows total ion current in the
negative mode vs. time obtained using liquid chromatography/mass spectrometry to analyze plasma from a single patient with an intact
colon (red line) as compared with a single patient who had a colectomy (blue line). The total ion current reflects the sum of all ions,
regardless of their individual mass, entering the mass spectrometer at each time point. Peaks reflecting the presence of large amounts of
indoxyl sulfate, a-N-phenylacetyl-glutamine, and p-cresol sulfate in the plasma from a dialysis patient with an intact colon are not seen in
the patient who had a colectomy. The lower figures illustrate the power of nontargeted mass spectrometry to detect individual solutes
identified by mass charge (m/z) ratio. They compare ion current at two m/z values obtained on analysis of plasma from nine hemodialysis
patients with intact colons (red lines) as compared with six hemodialysis patients who had colectomies (blue lines). The figure on the left
confirms that a-N-phenylacetyl-glutamine, m/z 263.1037, is present in lower concentration in patients who had colectomies. The identity of
this peak as a-N-phenylacetyl-glutamine was confirmed by analysis of a chemical standard. The figure on the right illustrates that a solute
with m/z 264.0876 is also present in much lower concentration in patients who had colectomies. No compound matching this m/z ratio is
included in standard databases of human metabolites and its identity remains to be determined. Note that the signal for this feature is of
much lower amplitude than that for a-N-phenylacetyl-glutamine and that it is found at a time point where no peak is visible on the total ion
chromatogram from the patient with a colon, although an unrelated peak is present on the total ion chromatogram from the patient who
had a colectomy. Nontargeted mass spectrometry reveals that the total ion chromatogram obtained from plasma samples is comprised of a
very large number of individual features including many of relatively low magnitude. Data are from the report of Aronov et al.21
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microbial metabolites and reagent standards for such
compounds are rarely available.
THE POTENTIAL TOXICITY OF COLON-DERIVED SOLUTES
Colon-derived uremic solutes that have been identified to
date are listed in Table 1. The list will get longer as more mass
spectrometric studies are performed. We will thus face an
increasingly large task in determining the extent to which any
of these solutes are toxic. Indoxyl sulfate has been shown to
be toxic in vitro, and levels of p-cresol sulfate have been
correlated with poor outcomes in dialysis patients.6,7,23,24
Recent studies have concentrated on the possibility that these
compounds cause vascular injury.11,25,26 The structural
relation of the uremic indoles and phenols to neurotrans-
mitters previously encouraged speculation that they impair
cognitive function, and it has recently been noted that they
could do this by interfering with cleansing of the brain
interstitium by the blood–brain barrier.27 A separate body of
work suggests that indoxyl sulfate injures renal tubular cells
and may thereby contribute to the progression of renal
insufficiency.11 While indoxyl sulfate and p-cresol sulfate are
the only colon-derived solutes that have been studied
extensively to date, recent metabolomic studies suggest that
other solutes derived from gut bacteria are also risk factors
for cardiovascular disease in humans and appear to have
causative roles as judged by animal studies.28
REDUCING THE LOAD OF COLON-DERIVED SOLUTES
Most efforts to lower uremic solute levels have focused
on increasing solute removal and ignored the alternate
strategy of suppressing solute production. Maneuvers to
suppress production, however, could prove particularly
effective for solutes that are made in an isolated body
compartment by microbes. In addition, maneuvers that
suppress the production of multiple colon-derived solutes
could be tested without first establishing which of these
solutes are most toxic.
One potential means to limit the production of colon-
derived solutes is to alter the food supplied to colon
microbes. The known colon-derived solutes are derived from
amino acids, as is illustrated for indoxyl sulfate and p-cresol
sulfate in Figure 1. On an ‘industrialized’ diet, the colon
microbes are supplied withB10 g of amino acids in the form
of incompletely digested proteins, sloughed intestinal cells,
and secretions.4,29 There is evidence that intestinal protein
absorption is impaired in renal failure, so that the portion of
ingested protein delivered to the colon microbes is in-
creased.30 One means to limit this supply is to restrict protein
intake. Before dialysis became available, uremic symptoms
were relieved by dietary protein restriction and reduced
production of colon-derived solutes may have contributed to
the effectiveness of this treatment. Protein restriction,
however, is unpalatable and can cause negative nitrogen
balance. Increasing dietary fiber intake could provide a
simpler and safer means to reduce the production of colon-
derived uremic solutes.31 The term fiber includes both
nonstarch polysaccharides and resistant starches that escape
digestion in the small intestine.31,32 Industrialized diets
contain less fiber than primitive diets, and dialysis patients
consume even less fiber than their healthy neighbors.33 With
low-fiber intake the supply of carbohydrates to the colon
microbes is low.34 With limited substrate for fermentation,
microbial growth is reduced and the volume of the stool, of
which microbes make up a major portion, is reduced. The
amount of amino acids needed for synthesis of microbial
protein is thus reduced, so that an increased portion of the
proteins and peptides delivered to the colon is converted into
uremic solutes. A prolonged transit time through the colon,
which results in part from lesser microbial growth, promotes
conversion of amino acids to uremic wastes.35 Increasing
dietary fiber intake is predicted to have the opposite effects
and to limit the conversion of amino acids to uremic solutes
while increasing microbial growth. Higher fiber intake could
account for the observation that urinary excretion of indoxyl
sulfate and p-cresol sulfate is lower in vegetarians than in
people eating an unrestricted diet. In dialysis patients,
supplementing the diet with 10–20 g/day of non-digestible
carbohydrates was recently shown to lower plasma levels of
p-cresol sulfate, which should encourage further efforts in this
direction.31 An interesting, but as yet unexplained, finding is
that production of the colon-derived solutes indoxyl sulfate
and p-cresol sulfate appears to be lower in patients on
peritoneal dialysis than in patients on hemodialysis.36
Another potential means to reduce the daily load of colon-
derived solutes is to administer sorbents that bind to
microbial metabolites. The carbon-based sorbent AST-120
reduces plasma levels of indoxyl sulfate and can also reduce
levels of p-cresol sulfate and other solutes.20 Clinical interest
in AST-120 is currently focused on testing whether it can
slow the progression of renal insufficiency. However, sorbents
could also be used to lower solute levels and improve health
Table 1 | Colon-derived uremic solutes
References
Indole compounds
Indoxyl sulfate 5, 20, and 21
Indoxyl glucuronide 21 and 45
5-Hydroxyindole 21
Indole-3-propionic acid 5
Phenyl compounds
p-Cresol sulfate 5, 20, and 21
p-Cresol glucuronide 46
Phenyl sulfate 5 and 20
Phenyl glucuronide 21
a-N-phenylacetyl-L-glutamine 5 and 21
Phenylpropionylglycine 5
Cinnamoylglycine 5 and 21
4-Ethylphenyl sulfate 20
Hippuric acid 5 and 20
This list, based heavily on references 5, 19, and 20, is certainly incomplete. Indole-3-
propionic acid and phenylpropionylglycine were identified by Wikoff et al.5 as
microbial products in rat plasma and other studies have demonstrated their
excretion in the urine. The results of Wikoff et al.5 suggest that hippuric acid is
largely of microbial origin in rats, but those of Aronov et al.21 suggest important
nonmicrobial production of hippuric acid in humans.
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in dialysis patients. Other maneuvers that could reduce the
production of colon-derived solutes include treatment with
laxatives to reduce transit time and antibiotics or ‘probiotic’
bacterial strains to alter the microbial population.6,32 A
particularly exciting possibility is that new knowledge of the
colon microbiome will permit redirection of solute produc-
tion by genetic manipulation of colon microbes.37 An
attractive feature of all these potential treatments is that
they could lower solute levels without the burden of
increasing dialysis duration and/or frequency.
LIVER AND KIDNEY
The liver and kidney together provide the body with an
organic waste disposal system. Remarkably similar symp-
toms, including prominent encephalopathy, are caused by
failure of either organ. Efforts to control uremic symptoms
by reducing solute production largely ended with the
development of dialysis. Hepatic encephalopathy, however,
is still treated by maneuvers designed to suppress waste solute
production. These maneuvers, moreover, are directed exclu-
sively toward solutes made by colon microbes. Their initial
target was ammonia, but other colon-derived solutes are
thought also to contribute to hepatic encephalopathy, and the
severity of symptoms is not well correlated with the plasma
level of any known solute. The maneuvers that have been
used to reduce solute production in liver failure include
colectomy, restriction of dietary protein, and administration
of non-digestible carbohydrates, laxatives, sorbents, antibio-
tics, and probiotics. These are the same maneuvers that could
be used to reduce colon-derived solute production in renal
failure, as described above. For many years, these maneuvers
were used in the liver failure without proof of their efficacy.
But controlled trials have recently established that the
nonabsorbed disaccharide lactulose and the antibiotic
rifaxamin maintain remission from hepatic encephalopa-
thy.38 Trials of maneuvers to suppress colon-derived solute
production in renal failure may have to be larger and/or
longer, given that symptoms of solute retention in dialysis
patients are less severe. However, the successful trials in the
liver failure show that chronic suppression of colon-derived
solute production is feasible and can be beneficial.
INCREASING THE REMOVAL OF COLON-DERIVED SOLUTES
The alternative to suppressing solute production is to
improve solute removal by dialysis. How easily this can be
accomplished depends on the nature of the solute and its
distribution in the body.39 Indoxyl sulfate and p-cresol
sulfate, the two best known colon-derived solutes, both bind
to plasma albumin. This binding is avid but reversible. More
than 90% of the solute in the plasma is bound to albumin at
any instant, but the bound portion is in rapid equilibrium
with the free portion. Because only free solutes are available
for diffusion through the dialysis membrane, the clearances
for indoxyl sulfate and p-cresol sulfate are only a small
fraction of the urea clearance during conventional dialysis.
However, the clearance of the bound solutes can be greatly
increased by increasing the dialysate flow and size of the
dialyzer.40,41 The clearance of bound solutes can also be
increased by combining high-volume ultrafiltration with
hemodialysis and by use of sorbents.42,43 Application of these
techniques could reduce the time-averaged concentrations of
bound solutes without increasing either the duration or
frequency of dialysis. The extent of protein binding has not
been evaluated for the majority of colon-derived solutes, but
some of those listed in Table 1, such as p-cresol glucuronide
and a-N-phenylacetyl-glutamine, are known not to be
protein bound. For these solutes, suppression of production
could provide a simpler means to lower solute levels than
increasing dialytic removal. Recent studies have documented
wide variability in the plasma levels of uremic solute levels
among individual patients with the same degree of renal
insufficiency, suggesting that solute production is variable
and should be susceptible to manipulation.44
CONCLUSION
Colon microbes produce a large number of organic
compounds that are foreign to mammalian cell metabolism.
Some of these compounds are absorbed in the colon and then
normally excreted from the body by the kidneys. The
possibility that accumulation of these compounds contri-
butes to uremic toxicity is strong enough to warrant trials of
the clinical effect of lowering their levels in the plasma.
DISCLOSURE
All the authors declared no competing interests.
ACKNOWLEDGMENTS
Support to this study was provided by the National Institutes of
Health (R21DK84439 and RO1 DK80123 to TWM and RO1 DK80123
to THH).
REFERENCES
1. Dethlefsen L, McFall-Ngai M, Relman DA. An ecological and evolutionary
perspective on human-microbe mutualism and disease. Nature 2007; 449:
811–818.
2. Goodman AL, Gordon JI. Our unindicted coconspirators: human
metabolism from a microbial perspective. Cell Metab 2010; 12: 111–116.
3. Walter J, Britton RA, Roos S. Host-microbial symbiosis in the vertebrate
gastrointestinal tract and the Lactobacillus reuteri paradigm. Proc Natl
Acad Sci USA 2011; 108(Suppl 1): 4645–4652.
4. Nordgaard I, Mortensen PB. Digestive processes in the human colon.
Nutrition 1995; 11: 37–45.
5. Wikoff WR, Anfora AT, Liu J et al. Metabolomics analysis reveals large
effects of gut microflora on mammalian blood metabolites. Proc Natl
Acad Sci USA 2009; 106: 3698–3703.
6. Evenepoel P, Meijers BK, Bammens BR et al. Uremic toxins originating
from colonic microbial metabolism. Kidney Int Suppl 2009; 76(Suppl 114):
S12–S19.
7. Schepers E, Glorieux G, Vanholder R. The gut: the forgotten organ in
uremia? Blood Purif 2010; 29: 130–136.
8. Kolff WJ. The Artificial Kidney. J. H. Kok: Kampen, 1946.
9. Chen TS, Chen PS. Intestinal autointoxication: a medical leitmotif. J Clin
Gastroenterol 1989; 11: 434–441.
10. Ludwig GD, Senesky D, Bluemle Jr LW et al. Indoles in ureamia:
identification by countercurrent distribution and paper chromatography.
Am J Clin Nutr 1968; 21: 436–450.
11. Niwa T. Indoxyl sulfate is a nephro-vascular toxin. J Ren Nutr 2010; 20:
S2–S6.
12. Vanholder R, Bammens B, de Loor H et al. Warning: the unfortunate end
of p-cresol as a uraemic toxin. Nephrol Dial Transplant 2011; 26:
1464–1467.
Kidney International (2012) 81, 949–954 953
TW Meyer and TH Hostetter: Colon-derived uremic solutes m in i rev iew
13. Niwa T, Maeda K, Ohki T et al. A gas chromatographic-mass spectrometric
analysis for phenols in uremic serum. Clin Chim Acta 1981; 110: 51–57.
14. Van Haard P, Pavel S. Chromatography of urinary indole derivatives.
J Chromatogr 1988; 429: 59–94.
15. Niwa T. Recent progress in the analysis of uremic toxins by mass
spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2009; 877:
2600–2606.
16. Rhee EP, Souza A, Farrell L et al. Metabolite profiling identifies markers of
uremia. J Am Soc Nephrol 2010; 21: 1041–1051.
17. Kikuchi K, Itoh Y, Tateoka R et al. Metabolomic analysis of uremic toxins
by liquid chromatography/electrospray ionization-tandem mass
spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2010; 878:
1662–1668.
18. Sato E, Kohno M, Yamamoto M et al. Metabolomic analysis of human
plasma from haemodialysis patients. Eur J Clin Invest 2011; 41: 241–255.
19. Wikoff WR, Nagle MA, Kouznetsova VL et al. Untargeted metabolomics
identifies enterobiome metabolites and putative uremic toxins as
substrates of organic anion transporter 1 (Oat1). J Proteome Res 2011; 10:
2842–2851.
20. Kikuchi K, Itoh Y, Tateoka R et al. Metabolomic search for uremic toxins as
indicators of the effect of an oral sorbent AST-120 by liquid
chromatography/tandem mass spectrometry. J Chromatogr B Analyt
Technol Biomed Life Sci 2010; 878: 2997–3002.
21. Aronov P, Luo FY, Plummer NS et al. Colonic contribution to uremic
solutes. J Am Soc Nephrol 2011; 22: 1769–1776.
22. Roux A, Lison D, Junot C et al. Applications of liquid chromatography
coupled to mass spectrometry-based metabolomics in clinical chemistry
and toxicology: a review. Clin Biochem 2011; 44: 119–135.
23. De Smet R, Van Kaer J, Van Vlem B et al. Toxicity of free p-cresol: a
prospective and cross-sectional analysis. Clin Chem 2003; 49: 470–478.
24. Bammens B, Evenepoel P, Keuleers H et al. Free serum concentrations of
the protein-bound retention solute p-cresol predict mortality in
hemodialysis patients. Kidney Int 2006; 69: 1081–1087.
25. Faure V, Dou L, Sabatier F et al. Elevation of circulating endothelial
microparticles in patients with chronic renal failure. J Thromb Haemost
2006; 4: 566–573.
26. Meijers BK, Van Kerckhoven S, Verbeke K et al. The uremic retention
solute p-cresyl sulfate and markers of endothelial damage. Am J Kidney
Dis 2009; 54: 891–901.
27. Hosoya KI, Tachikawa M. Roles of organic anion/cation transporters at the
blood-brain and blood-cerebrospinal fluid barriers involving uremic
toxins. Clin Exp Nephrol 2011; 15: 478–485.
28. Wang Z, Klipfell E, Bennett BJ et al. Gut flora metabolism of
phosphatidylcholine promotes cardiovascular disease. Nature 2011; 472:
57–63.
29. Chacko A, Cummings JH. Nitrogen losses from the human small bowel:
obligatory losses and the effect of physical form of food. Gut 1988; 29:
809–815.
30. Bammens B, Verbeke K, Vanrenterghem Y et al. Evidence for impaired
assimilation of protein in chronic renal failure. Kidney Int 2003; 64:
2196–2203.
31. Meijers BK, De Preter V, Verbeke K et al. p-Cresyl sulfate serum
concentrations in haemodialysis patients are reduced by the
prebiotic oligofructose-enriched inulin. Nephrol Dial Transplant 2009; 25:
219–224.
32. De Preter V, Hamer HM, Windey K et al. The impact of pre- and/or
probiotics on human colonic metabolism: does it affect human health?
Mol Nutr Food Res 2011; 55: 46–57.
33. Kalantar-Zadeh K, Kopple JD, Deepak S et al. Food intake characteristics
of hemodialysis patients as obtained by food frequency questionnaire.
J Ren Nutr 2002; 12: 17–31.
34. Elia M, Cummings JH. Physiological aspects of energy metabolism and
gastrointestinal effects of carbohydrates. Eur J Clin Nutr 2007; 61(Suppl 1):
S40–S74.
35. Stephen AM, Wiggins HS, Cummings JH. Effect of changing transit time
on colonic microbial metabolism in man. Gut 1987; 28: 601–609.
36. Pham NM, Recht NS, Hostetter TH et al. Removal of the protein-bound
solutes indican and p-cresol sulfate by peritoneal dialysis. Clin J Am Soc
Nephrol 2008; 3: 85–90.
37. Goodman AL, Kallstrom G, Faith JJ et al. Extensive personal human gut
microbiota culture collections characterized and manipulated in
gnotobiotic mice. Proc Natl Acad Sci USA 2011; 108: 6252–6257.
38. Riordan SM, Williams R. Gut flora and hepatic encephalopathy in patients
with cirrhosis. N Engl J Med 2010; 362: 1140–1142.
39. Meyer TW, Sirich TL, Hostetter TH. Dialysis cannot be dosed. Semin Dial
2011; 24: 471–479.
40. Meyer TW, Leeper EC, Bartlett DW et al. Increasing dialysate flow and
dialyzer mass transfer area coefficient to increase the clearance of
protein-bound solutes. J Am Soc Nephrol 2004; 15: 1927–1935.
41. Luo FJ, Patel KP, Marquez IO et al. Effect of increasing dialyzer
mass transfer area coefficient and dialysate flow on clearance of protein-
bound solutes: a pilot crossover trial. Am J Kidney Dis 2009; 53:
1042–1049.
42. Meijers BK, Bammens B, Verbeke K et al. A review of albumin binding in
CKD. Am J Kidney Dis 2008; 51: 839–850.
43. Meert N, Waterloos MA, Van Landschoot M et al. Prospective evaluation
of the change of predialysis protein-bound uremic solute concentration
with postdilution online hemodiafiltration. Artif Organs 2010; 34:
580–585.
44. Eloot S, Schepers E, Barreto DV et al. Estimated glomerular filtration rate is
a poor predictor of concentration for a broad range of uremic toxins. Clin
J Am Soc Nephrol 2011; 6: 1266–1273.
45. Niwa T, Miyazaki T, Tsukushi S et al. Accumulation of indoxyl-beta-D-
glucuronide in uremic serum: suppression of its production by
oral sorbent and efficient removal by hemodialysis. Nephron 1996; 74:
72–78.
46. Lesaffer G, De Smet R, Belpaire FM et al. Urinary excretion of
the uraemic toxin p-cresol in the rat: contribution of glucuronidation to
its metabolization. Nephrol Dial Transplant 2003; 18: 1299–1306.
47. Dawson LF, Donahue EH, Cartman ST et al. The analysis of para-cresol
production and tolerance in Clostridium difficile 027 and 012 strains. BMC
Microbiol 2011; 11: 86.
954 Kidney International (2012) 81, 949–954
min i rev iew TW Meyer and TH Hostetter: Colon-derived uremic solutes
